中国医药科学Issue(18)：213-216,4.
Rho激酶抑制剂对ST段抬高心肌梗死PCI中冠脉血流的影响
Rho-kinase inhibitor affect coronary blood flow to ST-segment elevation myocardial infarction
陈少源 1艾文 1方红城 1谢培益 1徐素玲 1陈菲 1邱小燕1
作者信息
- 1. 广东医学院附属深圳南山医院，广东深圳518052
- 折叠
摘要
Abstract
Objective To evaluate the efficacy and safety of the patients with acute ST-elevation myocardial infarction (STEMI) use Rho-kinase inhibitor in primary percutaneous coronary intervention (PCI). Methods 66 patients with STEMI ( both in the incidence of the 12-hour period) ready to receive primary PCI were randomly divided into two groups:control group(non-use of fasudil hydrochloride, n=33), fasudil hydrochloride group (intravenous infusion, n=33); the thrombolysis in myocardial infarction(TIMI) grade and corrected TIMI frame count(CTFC) were observed in PCI process, peak serum CKMB and cTNI levels, left ventricular ejection fraction(LVEF), hemorrhage event ,thrombocytopenia, low blood pressure and major adverse cardiovascular event (MACE) were also studied during hospital. Results The two groups with CTFC, CKMB, cTNI and LVEF were statistically significant(P=0.039, 0.045, 0.028, 0.049, respectively);TIMI grade, hospital MACE, low blood pressure, hemorrhage event and thrombocytopenia were no significant difference. Conclusion Application of fasudil hydrochloride during primary PCI in STEMI patients were safe and effective, which can improve myocardial perfusion.关键词
Rho激酶抑制剂/法舒地尔/急性ST段抬高心肌梗死/经皮冠状动脉介入治疗Key words
Rho-kinase inhibitor/Fasudil hydrochloride/Acute ST-elevation myocardial infarction/Percutaneous coronary intervention分类
医药卫生引用本文复制引用
陈少源,艾文,方红城,谢培益,徐素玲,陈菲,邱小燕..Rho激酶抑制剂对ST段抬高心肌梗死PCI中冠脉血流的影响[J].中国医药科学,2014,(18):213-216,4.
